Twist Bioscience (TWST) Company Report

Twist Bioscience reported $99 million in Q4 and $376.6 million in FY 2025 revenue, exceeding initial guidance by $7 million at the midpoint, with gross margin growing 20 percentage points over two years to above 50%. The company targets adjusted EBITDA break-even by Q4 2026.
The Next-Generation Sequencing (NGS) segment grew over 20% in FY 2025 to $208 million, but FY 2026 guidance implies about 12% growth due to a single customer's transition from clinical trials to commercial ramp. Excluding this customer, NGS grew almost 20% in 2025 and is expected to maintain a similar growth rate in FY 2026.
The DNA Synthesis and Protein Solutions (DSPS) segment grew 17% in FY 2025 and is guided for about 16% growth in FY 2026, supported by a record pharma order in Q4 2025 providing visibility for the first half of FY 2026.
Starting fiscal Q1 2026, Twist will provide more detailed disclosures on customer groups (therapeutic, diagnostics, OEM/distributor, academic/government) and pricing insights to offer greater transparency into growth drivers.

Nov 17, 2025, 8:20 PM

Transcript

Twist Bioscience Discusses Strong 2025 Performance and 2026 Outlook at Wolfe Research Conference

TWST

Guidance Update

Revenue Acceleration/Inflection

New Projects/Investments

Twist Bioscience reported $99 million in Q4 and $376.6 million for the full year 2025, exceeding its initial guidance by $7 million at the midpoint despite a challenging economic environment.
The company has significantly improved its gross margin by 20 points over the last two years, now exceeding 50%, and anticipates reaching Agility Beta Break-Even in Q4 2026. OPEX remained flat or slightly decreased from 2022 to 2025 while revenue grew 85%.
The Next-Generation Sequencing (NGS) segment's 12% growth guidance for fiscal year 2026 is impacted by a single customer's transition from clinical trials to commercial ramp, which is causing sequential noise from Q4 to Q1; excluding this customer, the NGS business grew almost 20% in 2025 and is expected to grow similarly in FY26.
Growth in the DNA Synthesis and Protein Solutions (DSPS) segment, which grew 17% last year and is guided for 16% growth this year, is driven by winning in the therapeutics area and the fragment market, leading to a lower average selling price (ASP) per gene, which the company views as a positive indicator of market penetration.
Starting fiscal Q1, Twist plans to introduce new disclosures on customer groups, including therapeutic, diagnostics, OEM, distributor, academic, and government segments, to provide more detailed insights into its growth drivers.

Nov 17, 2025, 8:20 PM

Transcript

Twist Reports Strong FY2025 Results, Updates 2026 Guidance, and Shifts R&D Focus

TWST

Guidance Update

Revenue Acceleration/Inflection

Demand Weakening

Twist reported Q4 revenue of $99 million and FY 2025 revenue of $376.6 million, exceeding its initial guidance midpoint by approximately $7 million.
The company significantly improved its gross margin by 20 points over the last two years, reaching above 50%, and targets adjusted EBITDA breakeven in Q4 2026.
The NGS segment grew over 20% in FY 2025 to $208 million (approximately 55% of sales), with a 12% growth projected for FY 2026, impacted by a single customer's transition from clinical trials to commercial ramp.
The DNA synthesis and protein solutions (DSPS) segment grew 17% last year (approximately 45% of sales) and is guided for 16% growth in FY 2026, supported by a significant pharma order in Q4 2025.
Twist is strategically refocusing its R&D efforts towards revenue growth, having successfully optimized gross margins to above 50%.

Nov 17, 2025, 8:20 PM

Transcript

Twist Discusses Strong FY2025 Performance, NGS Customer Impact, and 2026 Outlook

TWST

Guidance Update

Revenue Acceleration/Inflection

New Projects/Investments

Twist reported Q4 revenue of $99 million and FY2025 revenue of $376.6 million, exceeding initial guidance. The company has significantly improved its gross margin by 20 percentage points over the last two years to above 50% and aims for adjusted EBITDA break-even in Q4 2026.
The Next-Generation Sequencing (NGS) segment, which accounted for $208 million (55% of sales) and grew over 20% last year, is guided for approximately 12% growth in FY2026. This guidance is impacted by a single customer transitioning from clinical trials to commercial ramp, which caused a sequential drop from Q4 to Q1; excluding this customer, the NGS business grew almost 20% in 2025 and is expected to do so in 2026. This customer represents $5 million or more per quarter.
The DNA Synthesis and Protein Solutions (DSPS) segment, representing 45% of sales, grew 17% last year and is guided for about 16% growth this year. A pretty big pharma order in Q4, a new record for the company, provides strong visibility for the first half of the year in this segment. The price per gene was down about 11% in Q4 primarily due to increased wins in the therapeutics area and the fragments market.
Twist achieved 85% revenue growth from 2022 to 2025 while maintaining flat OPEX (down $1 million) and improving gross margin from under 30% to over 50%. With gross margins now above 50%, the company plans to refocus R&D efforts towards revenue growth.

Nov 17, 2025, 8:20 PM

Transcript

Twist Discusses Strong FY2025 Performance and 2026 Outlook at Wolfe Research Conference

TWST

Guidance Update

Revenue Acceleration/Inflection

New Projects/Investments

Twist reported $99 million in revenue for Q4 2025 and $376.6 million for fiscal year 2025, exceeding its initial guidance midpoint by $7 million despite a challenging economic environment.
The company has significantly improved its gross margin by 20 points over the last two years, reaching over 50%.
Twist aims to achieve Agility Beta Break-Even in Q4 2026, having reduced its loss to $8 million in the last quarter.
The Next-Generation Sequencing (NGS) segment's Q4 to Q1 sequential drop and 2026 guidance are impacted by a single customer transitioning from clinical trials to commercial ramp; however, the business, excluding this customer, is growing at nearly 20%.
The DNA Synthesis and Protein Solutions (DSPS) segment secured a record-breaking pharma order in Q4 2025, providing strong visibility for the first half of 2026, with a lower average selling price (ASP) driven by winning in therapeutics/AI and fragment markets.

Nov 17, 2025, 8:20 PM

Transcript

Twist Bioscience Discusses FY25 Performance and 2026 Outlook at Wolfe Research Conference

TWST

Guidance Update

Revenue Acceleration/Inflection

New Projects/Investments

Twist Bioscience reported $99 million in Q4 revenue and $376.6 million for the full year 2025, exceeding its initial guidance by $7 million at the midpoint.
The company achieved a 20 percentage point increase in gross margin over the last two years, now exceeding 50%, and aims for adjusted EBITDA break-even by Q4 2026.
The Next-Generation Sequencing (NGS) segment grew over 20% in FY 2025 to $208 million but is guided to about 12% growth for FY 2026 due to a specific customer's transition from clinical trials to commercialization. Excluding this customer, NGS growth is closer to 20%.
The DNA Synthesis and Protein Solutions (DSPS) segment grew 17% in FY 2025 and is guided for about 16% growth in FY 2026, bolstered by a record pharma order in Q4 2025 that provides strong visibility for the first half of 2026.
The 11% decline in price per gene in Q4 2025 for DSPS is attributed to increased sales in therapeutics and the fragment market, which the company views as a positive indicator of market penetration.

Nov 17, 2025, 8:20 PM

Transcript

Twist Bioscience Reports Record Q4 and Full-Year 2025 Revenue, Provides FY 2026 Guidance

TWST

Earnings

Guidance Update

Revenue Acceleration/Inflection

Twist Bioscience reported record Q4 2025 revenue of $99 million, a 17% year-over-year increase, and full-year 2025 revenue of $376.6 million, marking 20% growth over fiscal 2024.
The company achieved a gross margin of 51.3% for Q4 2025 and 50.7% for FY 2025, an 8 percentage point increase compared to fiscal 2024, and reduced its adjusted EBITDA loss to $46.9 million for FY 2025, an improvement of $46.6 million from fiscal 2024.
For fiscal 2026, Twist Bioscience expects total revenues of $425 million-$435 million, representing 13%-15.5% growth, and anticipates reaching adjusted EBITDA breakeven by the end of fiscal 2026.
Q1 2026 revenue is projected to be $100 million-$101 million, with growth of 13%-14% year over year, though this quarter's revenue will be impacted by a large cancer diagnostics customer transitioning their assay from research to commercial.
Beginning in Q1 2026, the company will introduce new revenue reporting categories, combining Synbio and Biopharma into DNA synthesis and protein solutions, and renaming NGS to NGS applications, along with new industry groupings.

Nov 14, 2025, 1:00 PM

Transcript

Twist Bioscience Reports Q4 and FY 2025 Results, Provides FY 2026 Guidance

TWST

Earnings

Guidance Update

Product Launch

Twist Bioscience reported a record fourth quarter 2025 revenue of $99 million, an increase of 17% year-over-year, and full fiscal year 2025 revenue of $376.6 million, growing 20% over fiscal 2024.
The company achieved a full fiscal year 2025 gross margin of 50.7%, a significant increase from 42.6% in fiscal 2024, demonstrating continuous margin improvement.
Adjusted EBITDA for fiscal 2025 was a loss of approximately $46.9 million, an improvement of approximately $46.6 million compared to fiscal 2024, with a goal to reach adjusted EBITDA breakeven by the end of fiscal 2026.
For fiscal 2026, the company expects total revenues between $425 million and $435 million, representing 13%-15.5% year-over-year growth, and projects gross margin to be above 52%.
Twist Bioscience plans to commercially introduce an MRD Express product for minimal residual disease in early calendar 2026, offering rapid individualized panel manufacturing, and will implement new revenue groupings: "DNA synthesis and protein solutions" and "NGS applications" starting Q1 2026.

Nov 14, 2025, 1:00 PM

Transcript

Twist Bioscience Reports Q4 and Full Year 2025 Financial Results, Provides FY2026 Guidance

TWST

Earnings

Guidance Update

Revenue Acceleration/Inflection

For Q4 FY2025, Twist Bioscience reported $99.0 million in revenue, exceeding its guidance of ~$96-98 million, with a 51.3% gross margin and an Adjusted EBITDA of $(7.8) million, which was within its guidance range.
For the full fiscal year 2025, the company achieved $376.6 million in revenue, meeting its guidance of ~$374-376 million, and a gross margin of 50.7%, also within guidance.
As of September 30, 2025, Twist Bioscience held $232.4 million in cash, cash equivalents, and short-term investments.
The company provided FY2026 revenue guidance of $425 to $435 million and anticipates achieving approximately $0 Adjusted EBITDA in Q1 FY2026.

Nov 14, 2025, 1:00 PM

Presentation

Twist Bioscience Reports Record Q4 and Full-Year 2025 Results, Provides FY 2026 Guidance

TWST

Earnings

Guidance Update

Product Launch

Twist Bioscience reported record Q4 2025 revenue of $99 million, an increase of 17% year-over-year, and full-year 2025 revenue of $376.6 million, up 20% from fiscal 2024.
Gross margin for Q4 2025 was 51.3%, with the full-year margin at 50.7%, an 8-point increase over fiscal 2024, and is expected to remain above 52% for fiscal 2026.
The company significantly improved its adjusted EBITDA, reporting a loss of $7.8 million in Q4 2025 and a loss of $46.9 million for the full fiscal year 2025, with a target to reach adjusted EBITDA breakeven by the end of fiscal 2026.
For fiscal year 2026, Twist Bioscience expects total revenues between $425 million and $435 million, representing 13%-15.5% year-over-year growth, with DNA Synthesis and Protein Solutions projected to grow 15%-18% and NGS Applications 11%-13.5%.
Twist Bioscience plans to commercially introduce its MRD Express product in early calendar 2026 and noted that orders from customers working on AI discovery projects grew over $25 million in fiscal 2025 compared to fiscal 2024.

Nov 14, 2025, 1:00 PM

Transcript

Earnings Transcripts

Quarterly earnings call transcripts for Twist Bioscience.

Q4 2025

Nov 14, 2025

→

Q3 2025

Aug 4, 2025

→

Q2 2025

May 5, 2025

→

View All Transcripts

Ask Fintool AI Agent

Get instant answers from SEC filings, earnings calls & more

What did Emily Leproust say about margins?What are Twist Bioscience's strategic priorities?How is Twist Bioscience positioned vs competitors?How did Twist Bioscience do last quarter?

Twist Bioscience (TWST)

Analyst Earnings Quarterly Reports

Q4 2025

Q3 2025

Q2 2025

Q1 2025

Executives

Emily Leproust

Adam Laponis

Dennis Cho

Patrick Finn

Paula Green

Robert Werner

Board Members

Jan Johannessen

Keith Crandell

Melissa Starovasnik

Nelson Chan

Robert Chess

Robert Ragusa

Trynka Shineman Blake

Analyst Coverage

Vijay Kumar

Brendan Smith

Puneet Souda

Luke Sergott

Catherine Schulte

Matthew Larew

Matthew Sykes

Matt Larew

Subbu Nambi

Subhalaxmi Nambi

Sung Ji Nam

Douglas Schenkel

Doug Schenkel

Mac Etoch

Sam Wan

Thomas Peterson

Chad Wiatrowski

Madeline Mollman

Rachel Vatnsdal Olson

Thomas DeBourcy

Tom DeBourcy

Tom Peterson

Latest news

Earnings Transcripts

Q4 2025

Q3 2025

Q2 2025

Ask Fintool AI Agent